Login to Your Account

Another Amgen patent win shakes up the PCSK9 space

By Marie Powers
News Editor

Friday, January 6, 2017

The decision by the U.S. District Court in Delaware to issue a permanent injunction against the manufacturing or sale of Praluent in the U.S. dented shares of developers Sanofi SA and Regeneron Pharmaceuticals Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription